The FDA has approved a new dosing regimen for Eylea, an injectable drug to treat degenerative eye diseases such as wet age-related macular degeneration. This means people taking the drug may need these eye injections less frequently.
Izervay, a second drug to treat the advanced and severe form of dry macular degeneration known as geographic atrophy, has received full FDA approval, opening another avenue of hope for people with this vision-stealing condition.
For the first time, a research team has created laboratory-grown cone photoreceptor cells that respond to light, unlocking a potential new way to treat macular degeneration.
A BrightFocus-funded research team has identified how an FDA-approved antioxidant may be used to help prevent age-related macular degeneration in people with certain genetic risk factors for the disease.
Factors that stress the body, such as obesity, can make people more likely to develop macular degeneration when they’re older, even if they’ve returned to a normal weight, new research shows.
A recent study reveals that an anti-inflammatory drug approved to treat certain autoimmune diseases can counteract a protein in the body that’s linked to age-related macular degeneration. These findings may lead to a new treatment option for the disease.
The U.S. Food and Drug Administration in November granted Breakthrough Therapy designation for a new treatment that could slow the progression of geographic atrophy, an advanced and severe form of dry age-related macular degeneration that can lead to permanent vision loss.
David Liao, MD, offers insights into managing and understanding AMD and what forthcoming FDA approval could mean for treatment.